BTOG 2022 | Adjuvant atezolizumab in NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the impact of the approval of atezolizumab in UK patients with PD-L1-positive non-small cell lung cancer (NSCLC). Approval of the anti-PD-L1 antibody in England was made possible via Project Orbis, and atezolizumab demonstrated superior disease-free survival in the IMpower010 trial (NCT02486718). Prof. Popat additionally highlights the need for PD-L1 testing to identify patients who will benefit from this treatment. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.